by Elana Gotkine Credit: CC0 Public Domain For patients with haploidentical hematopoietic cell transplantation (haplo-HCT), the addition of itacitinib to standard graft versus host disease (GvHD) prophylaxis is well tolerated and results in low rates of cytokine release syndrome (CRS), according to a study published online Nov. 2 in Blood. Noting that posttransplant cyclophosphamide (PtCy) has improved GvHD prophylaxis in...
Tag: <span>stem cell transplant</span>
Post
Clinical trial tests new drug to reduce side effect of ‘half-matched’ stem cell transplants
by Julia Evangelou Strait, Washington University School of Medicine Credit: CC0 Public Domain Adding a new drug to standard care for stem cell transplant recipients may reduce a life-threatening side effect, according to an early-stage clinical trial conducted at Washington University School of Medicine in St. Louis. The trial showed that patients being treated for various...
Post
Certain combinations of gut bacteria protect stem cell transplant patients from immune reactions, finds study
by Technical University Munich Intestinal tissue during a graft-versus-host reaction: Donor cells (red) attack the body of the patient. Credit: Sebastian Jarosch, Dirk Busch / TUMAfter stem cell transplantation, the donated immune cells sometimes attack the patients’ bodies. This is known as graft versus host disease or GvHD. Researchers at the Technical University of Munich (TUM)...
Post
Study shows stem cell transplant significantly improves outcomes in refractory juvenile systemic sclerosis
by American College of Rheumatology Credit: CC0 Public Domain New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant.Juvenile-onset systemic sclerosis (jSSc), also called scleroderma, is a disfiguring autoimmune disorder...
Post
Risk biomarkers could predict serious side effect of stem cell transplant
by Leslie Cantu, Medical University of South Carolina This shows a section of the sinusoid in steady state, sinusoidal narrowing after endothelial damage due to conditioning regiment and alloreactivity, and at the stage of SOS with sinusoidal obstruction. Credit: Sophie Paczesny Doctors are one step closer to having a risk biomarker to alert them to which...
Post
Meningref trial shows better protection against meningococcal infection in hematopoietic stem cell transplant recipients
INSTITUT PASTEUR The team in the Hematology Department at Henri Mondor AP-HP Hospital, coordinated by Dr. Christine Robin, and scientists from the Institut Pasteur (the Invasive Bacterial Infections Unit led by Professor Muhamed-Kheir Taha) recently studied protection against meningococcal infection in patients who had received hematopoietic stem cell transplantation. The results of this trial (NCT03509051), sponsored by...
Post
Improved survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant
by Dana-Farber Cancer Institute Credit: Pixabay/CC0 Public Domain Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option....
Post
Genomic features of AML in patients over age 60 can predict success of stem cell transplant
Genomic profiles can be used to classify patients by risk of relapse after transplant DANA-FARBER CANCER INSTITUTE For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute...
Post
MS stem cell treatment stabilises disease and reduced disability, trial shows
Pioneering international research has found stem cell treatment in people with active multiple sclerosis stabilises the disease and improves disability. The first ever international large scale randomised trial into autologous haematopoietic stem cell transplantation (AHSCT) in relapsing remitting multiple sclerosis (MS) has shown that the treatmentstabilised the disease and improved disability in people who had experienced...
Post
New antiviral drug cuts cytomegalovirus infection, improves survival in patients undergoing donor stem cell transplant
In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has shown that a novel agent can protect against the most common viral infection that patients face after transplantation. The results represent a breakthrough in...